TY  - JOUR

T1  - Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - https://eprints.whiterose.ac.uk/108863/

PY  - 2017/01/01

AU  - Tappenden P

AU  - Harnan S

AU  - Ren S

AU  - Thokala P

AU  - Wong R

AU  - Mukuria C

AU  - Green C

AU  - Pledge S

AU  - Tidy J

ED  - 

DO  - DOI: 10.1007/s40273-016-0440-x

VL  - 35

IS  - 1

SP  - 97

EP  - 109

Y2  - 2024/12/22

ER  -